Share on StockTwits

Shares of Impax Laboratories (NASDAQ:IPXL) have been given a consensus recommendation of “Hold” by the sixteen analysts that are presently covering the company, Analyst Ratings Network.com reports. Eight analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $27.34.

Shares of Impax Laboratories (NASDAQ:IPXL) opened at 28.94 on Friday. Impax Laboratories has a 1-year low of $19.39 and a 1-year high of $31.04. The stock’s 50-day moving average is $29.05 and its 200-day moving average is $26.32. The company has a market cap of $1.967 billion and a price-to-earnings ratio of 1312.73.

Impax Laboratories (NASDAQ:IPXL) last announced its earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.05 by $0.19. The company had revenue of $118.70 million for the quarter, compared to the consensus estimate of $97.80 million. During the same quarter in the prior year, the company posted $0.37 earnings per share. The company’s quarterly revenue was down 20.1% on a year-over-year basis. On average, analysts predict that Impax Laboratories will post $0.88 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at ISI Group raised their price target on shares of Impax Laboratories to $35.00 in a research note on Thursday, July 3rd. They now have a “hold” rating on the stock. Separately, analysts at WallachBeth Capital raised their price target on shares of Impax Laboratories from $32.00 to $35.00 in a research note on Thursday, July 3rd. They now have a “buy” rating on the stock. Finally, analysts at Wells Fargo & Co. initiated coverage on shares of Impax Laboratories in a research note on Tuesday, June 10th. They set a “market perform” rating on the stock.

Impax Laboratories Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products, referred to as generics, in addition to the development and marketing of branded products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.